Valuation: ProPhase Labs, Inc.

Market Cap 698K 604K 565K 516K 973K 66.57M 988K 6.62M 2.6M 33.3M 2.62M 2.56M 111M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.23M 7.99M 7.47M 6.82M 12.86M 880M 13.06M 87.54M 34.35M 440M 34.64M 33.89M 1.47B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day+42.29%
1 week+20.14%
Current month+19.23%
1 month-34.56%
3 months-58.67%
6 months-71.53%
Current year-88.87%
1 week 0.03
Extreme 0.0301
0.05
1 month 0.03
Extreme 0.0301
0.08
Current year 0.03
Extreme 0.0301
0.47
1 year 0.03
Extreme 0.0301
6.66
3 years 0.03
Extreme 0.0301
74.8
5 years 0.03
Extreme 0.0301
152.5
10 years 0.03
Extreme 0.0301
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
9/9/25 Free

Chief Executive Officer

500,000 1.2036%
17/2/25 Free

Chief Operating Officer

500,000 1.6737%
14/2/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
+42.29%+20.14%-98.40%-99.92% 698K
-1.16%+17.75%+109.51%+496.83% 45.89B
+0.67%+4.52%+20.86%+50.13% 26.06B
+0.89%+2.31%-18.00%-33.80% 7.82B
+6.76%+15.69%+44.83%+142.18% 6.08B
-0.21%+3.12%+21.05%+69.56% 3.42B
+1.04%+14.77%-25.92%+1,363.91% 2.32B
+0.36%+4.99%+186.72%+17.90% 2.14B
+6.83%+12.50%+2.48%-51.72% 2.13B
-0.69%+8.98%+31.15%+21.81% 2.01B
Average +5.67%+273.60%+27.43%+197.69% 9.79B
Weighted average by Cap. +0.28%+296.69%+63.14%+286.98%

Financials

2024 2025
Net sales 6.77M 5.86M 5.48M 5.01M 9.43M 646M 9.58M 64.24M 25.21M 323M 25.42M 24.87M 1.08B 4.34M 3.76M 3.52M 3.21M 6.06M 414M 6.15M 41.23M 16.18M 207M 16.32M 15.96M 690M
Net income -53.36M -46.2M -43.18M -39.46M -74.37M -5.09B -75.53M -506M -199M -2.55B -200M -196M -8.48B -14.74M -12.76M -11.93M -10.9M -20.55M -1.41B -20.87M -140M -54.89M -703M -55.36M -54.15M -2.34B
Net Debt 23.9M 20.69M 19.34M 17.67M 33.3M 2.28B 33.82M 227M 88.97M 1.14B 89.72M 87.77M 3.8B 8.53M 7.38M 6.9M 6.31M 11.88M 813M 12.07M 80.92M 31.75M 407M 32.02M 31.32M 1.36B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
10/08/26 USD 0.0498 +42.29% 68,655
07/08/26 USD 0.0350 -23.91% 525,359
06/08/26 USD 0.0460 +5.07% 140,017
05/08/26 USD 0.0438 -8.79% 132,081
04/08/26 USD 0.0480 +15.80% 18,898

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock